Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Clinical Trials in Turkey / NCT05215197
Recruiting Not applicable

Intracochlear Platelet-rich Fibrin Application in Cochlear Implantation

NCT05215197 · tracked via the Priya Life Science Turkey tracker
Sponsor
Pamukkale University
Phase
Not applicable
Started
2022-01-31
Last updated
2026-07-14

Condition(s) studied

Hearing Loss, Sensorineural

Investigational drug(s) / intervention(s)

intracochlear platelet rich fibrin administration

intracochlear platelet rich fibrin administration: intracochlear platelet rich fibrin administration during routine cochlear implantation surgery

Study summary

Fibrosis due to surgical trauma is a common problem with cochlear implants. Fibrosis limits the effectiveness of implant and increases the power consumption. Our aim in this study is to benefit from the anti-inflammatory effects of autologous platelet-rich fibrin to reducing the fibrotic cascade.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients with sensorineural hearing loss * Patients who will have cochlear implant surgery with CI422 electrode Exclusion Criteria: * Patients with cochlear abnormality * Patients with auditory neuropathy

Primary outcome measure(s)

  • Electrode Impedance(Ohm) — 1-6 months
    All intra-operative impedance values will be acquired after surgery. They will be repeated in first week, 1, 3 and 6th months

Trial sites (1)

FacilityCityRegionStatus
Pamukkale University Denizli Turkey (Türkiye) Recruiting

More Pamukkale University trials in Turkey

INTRANASAL FLUTICASONE VERSUS FLUTICASONE-AZELASTINE COMBINATION Active, not recruiting
Connective Tissue Massage and Music-Based Progressive Muscle Relaxation in Primary Dysmenorrhea Recruiting
Health Literacy Level and Functional Outcomes in Patients With Hand and Forearm Injuries Recruiting
Functional Improvement and Fine Dexterity in Thumb Tendon Injuries Starting soon
The Effect of Kinesio Taping on Hand Functions in Zone V-VI Extensor Tendon Injuries Starting soon
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05215197 on ClinicalTrials.gov ↗ ← All trials in Turkey